[Daiichi Industrial Pharmaceutical] Revision of Full-Year Earnings Forecast for 2027 | Sales of ¥5.2 billion (Up 26.8% YoY)

Overview of Performance

Daiichi Industrial Pharmaceutical revised its full-year earnings forecast for the fiscal year ending March 2027 during the second quarter, projecting substantial increases in sales and profits driven by growth in the Electronics & Information segment and the Environment & Energy segment for high value-added products. Sales are expected to reach ¥52,000 million (up 26.8% YoY), operating income ¥7,500 million (up 50.0%), and net income ¥4,700 million (up 56.7%). These results are primarily due to price revisions and temporary demand increases, and ongoing attention to external factors affecting the business environment is necessary.

Outlook and Impact on Shareholders

The upward revision of the full-year outlook anticipates increases in sales and profits, likely leading to positive effects on dividends and stock prices for shareholders. However, considering external factors such as Middle East geopolitical developments and currency fluctuations, the company will continue to operate cautiously. Backed by strong second-quarter results, Daiichi Industrial Pharmaceutical aims to expand sales of high value-added products and implement pricing strategies to achieve sustainable growth.